In this single-blind, randomized trial, undertaken in China with 8-week interventions and follow-up to 52 weeks, about 2,200 providers will be randomly allocated to the intervention or control group.
Full Title of Study: “Boosting Chinese Healthcare Service Providers’ Utilization of Behavioral and Pharmacotherapy Interventions for Cigarette Smoking Cessation by ‘WeChat WeQuit’ Program”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Health Services Research
- Masking: Single (Investigator)
- Study Primary Completion Date: April 30, 2020
Previous studies have been showed that providing behavioral and pharmacotherapy interventions for cigarette smoking patients was effective but rare among Chinese healthcare service providers. In order to minimize the huge gap between the shortage and demand for smoking cessation training program and smoking cessation service, this 'WeChat WeQuit' smoking cessation training program has been designed to assess whether it will increase Chinese healthcare service providers' utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation or not.
In this single-blind, randomized trial, about 2200 HSPs will be randomly selected (by randomizeR, https://CRAN.R-project.org/package=randomizeR) to 8-week intervention (behavioral and pharmacotherapy interventions for cigarette smoking patients to help them quit smoking) group or control group that only communicates without any standard smoking cessation practices related messages, and follow-up to 52 weeks. The trial will be carried out in into two phases, the first phase is the pilot study (n=200, 8-week intervention and follow-up to 16 weeks) and the second is the main study (n=2000, 8-week intervention and follow-up to 52 weeks). It is hypothesized that 'WeChat WeQuit' training program will improve Chinese HSPs' utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation and increase quit rate for smoking patients.
- Behavioral: ‘WeChat WeQuit’ smoking cessation training program
- Providing ‘WeChat WeQuit’ smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
Arms, Groups and Cohorts
- Experimental: With smoking cessation training
- Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
- No Intervention: Without smoking cessation training
- Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.
Clinical Trial Outcome Measures
- The effectiveness of ‘WeChat WeQuit’ training program.
- Time Frame: 52 weeks
- The utilization rate (i.e. rate=smokers treated divided by smokers seen) of behavioral and pharmacotherapy interventions by HSP for smoking patients from 8 to 52-week.
- Prevalence of smoking abstinence
- Time Frame: 24 weeks
- The proportion of smoking patients with 7-day point prevalence smoking abstinence (not even a puff of smoke, for the last 7 days) at 4, 8, 12, 16, 20 and continuously abstinence assessed at 24-weeks follow-up.
Participating in This Clinical Trial
1. Chinese-speaking healthcare service providers
2. Know how to use WeChat
3. Use WeChat on a daily basis
4. Willing to provide informed consent to participate in the study
1. Non-Chinese speakers
2. Not healthcare service providers
3. Do not use WeChat
4. Unwilling to participate in the study
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Central South University
- Provider of Information About this Clinical Study
- Principal Investigator: Yanhui Liao, Associate professor – Central South University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.